Navigation Links
Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
Date:3/2/2009

ed to the company's proprietary product candidates; and (v) the preliminary Phase 2 results for NKTR-118 described in this press release remain subject to completion of final data gathering and analysis and therefore this data remains subject to change. Other important risks and uncertainties are detailed in the company's reports and other filings with the Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K.

Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise. For more information on Nektar Therapeutics, please visit http://www.nektar.com.

    Jennifer Ruddock, 650-631-4954
    Nektar Therapeutics

    Susan A. Noonan, 212-966-3650
    The SAN Group


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
2. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
3. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
4. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
5. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
6. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
7. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
8. TissueGene Announces Regulatory Allowance to Initiate Phase IIa Study of TG-C in South Korea for Osteoarthritis of the Knee
9. Pharmaxis Announces New Drug Application Submission for Aridol(TM)
10. Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
11. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
(Date:1/22/2015)... 22, 2015  ViewRay™, a privately held medical device company, ... distributor agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: ... the treatment of cancer in Japan ... world,s first and only MRI-guided radiation therapy system that ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... sodium injection) were also ... within 90 days-, BRIDGEWATER, N.J., Dec 10 ... total hospital,direct medical costs associated with VTE treatment are ... the use of low-molecular weight heparin,(LMWH) vs. unfractionated heparin ...
... 10 Alfacell Corporation,(Nasdaq: ACEL ) today reported ... The company recorded a net loss of approximately ... for the fiscal quarter ended Oct. 31,compared to a ... and diluted,common share, for the first quarter of fiscal ...
Cached Medicine Technology:Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 2Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 3Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 4Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 5Alfacell Reports Financial Results for First Quarter of Fiscal 2008 2Alfacell Reports Financial Results for First Quarter of Fiscal 2008 3Alfacell Reports Financial Results for First Quarter of Fiscal 2008 4Alfacell Reports Financial Results for First Quarter of Fiscal 2008 5
(Date:1/22/2015)... 2015 AngelWeddingDress, the premier women’s dress ... wedding dresses. View website of AngelWeddingDress.com to ... maternity wedding dresses online for a bridal party. AngelWeddingDress ... quality for them. Its maternity wedding dresses are specially ...
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... 2015 Yesterday, Senator Holly Mitchell ... Kristin Olsen (R-Modesto) were honored by the California ... biotechnology, biomedical science, medical device and pharmaceutical innovation ... the “2014 Life Sciences Champion” award from CHI ...
(Date:1/22/2015)... 22, 2015 EBSCO Information Services ... expanding their relationship in an effort to further promote visibility ... While EBSCO has long made AMA journals available via its ... for The JAMA Network. , Long known as ...
(Date:1/22/2015)... 22, 2015 Step into a macabre ... Science Museum of Virginia. Wicked Plants, the Museum’s latest ... unearths 75 poisonous, carnivorous and diabolical plants inside of ... to uncover the biochemical, physical and neurological processes between ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... folic acid fortification of enriched grains in the mid 1990s, ... and Canada with neural tube defects has declined by 20 ... institution of fortification, however, the rate at which new cases ... report researchers at the Jean Mayer USDA Human Nutrition Research ...
... of the journal Cancer Cell, published by Cell Press ... promyelocytic leukemia (APL) and identifies promising new avenues to ... ,Results from two new studies provide key mechanistic ... deadly type of leukemia.,APL is a cancer of the ...
... issue of the journal Cancer Cell, published by Cell ... potency and effectiveness of a tumor necrosis factor (TNF) ... , A new study identifies a combination ... promising treatment currently being used in clinical trials. ...
... to boost fruit and vegetable intake among young children could have ... Janet Cade and colleagues of Leeds University assessed the impact of ... 3,700 young students from 98 schools in the north of England. ... and nutrient intake. , It was seen that ...
... protect against the clustering of abnormal body chemistry known as ... of Epidemiology and Community Health. ,The syndrome has been ... and premature death. ,The findings are based on ... 59, all of whom were part of a long term ...
... Brandeis University study published in the July issue of ... require screening for substance abuse and mental health in ... , This may be a missed opportunity to ... only a fraction of whom currently receive treatment. ...
Cached Medicine News:Health News:Folicacid Fortification Very Beneficial 2Health News:Folicacid Fortification Very Beneficial 3Health News:Insights into Acute Promyelocytic Leukemia 2Health News:Insights into Acute Promyelocytic Leukemia 3Health News:New Cancer Therapy in Clinical Trial 2Health News:Britains Free Fruit -And -Vegetable -Scheme Falls Flat 2Health News:Screening for Behavioral Health 2
Blunt tipped forceps wlth a small grasping platform on each tip. For grasping fine membranes or grasping membranes adherent to the retinal surface....
Blunt tipped forceps with small, slightly rounded tips angled perpendicular to the shaft. For grasping peripheral membranes....
... Microdiathermy System features an advanced design, solid ... as well as many years of clinical ... optimum choice for the placement of discrete ... burns produce the maximum effect at the ...
Anterior chamber protein cell meter. Laser flare meter and cell-counting functions are included in this cell meter, with dramatically enhanced measurement of cell volume....
Medicine Products: